CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia
- 490 Downloads
Acute myeloid leukemia (AML) is the most common form of acute leukemia with dismal long-term prognosis with age. The most aggressive subtype of AML is MLL-AML that is characterized by translocations of the mixed-lineage leukemia gene (MLL) and resistance to conventional chemotherapy. Cyclin dependent kinase 9 (CDK9) plays a crucial role in the MLL-driven oncogenic transcription, and hence, inhibiting activity of CDK9 has been proposed as a promising strategy for treatment of AML. We investigated the therapeutic potential of CDKI-73, one of the most potent CDK9 inhibitors, against a panel of AML cell lines and samples derived from 97 patients. CDKI-73 induced cancer cells undergoing apoptosis through transcriptional downregulation of anti-apoptotic proteins Bcl-2, Mcl-1 and XIAP by majorly targeting CDK9. Contrastively, it was relatively low toxic to the bone marrow cells of healthy donors. In MV4–11 xenograft mouse models, oral administration of CDKI-73 resulted in a marked inhibition of tumor growth (p < 0.0001) and prolongation of animal life span (P < 0.001) without causing body weight loss and other overt toxicities. The study suggests that CDKI-73 can be developed as a highly efficacious and orally deliverable therapeutic agent for treatment of AML.
KeywordsCDKI-73 CDK9 AML MLL-AML MV4–11 xenograft Apoptosis
Muhammed H. Rahaman and Longjin Zhong acknowledge the support from the Australian Government Research Training Program Scholarship. We especially acknowledge the contribution of patients.
This work was partially supported by Channel 7 Children’s Research Foundation (Grant number 161300) and the Tour de Cure’s established Grant to SW.
Compliance with ethical standards
Conflicts of interest
The authors have no conflicts of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
“Informed consent was obtained from all individual participants included in the study.”
- 2.Derolf ÅR, Kristinsson SY, Andersson TM-L, Landgren O, Dickman PW, Björkholm M (2009) Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 113(16):3666–3672. https://doi.org/10.1182/blood-2008-09-179341 CrossRefGoogle Scholar
- 6.Horton SJ, Jaques J, Woolthuis C, van Dijk J, Mesuraca M, Huls G, Morrone G, Vellenga E, Schuringa JJ (2013) MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia 27(5):1116–1126. https://doi.org/10.1038/leu.2012.343 CrossRefGoogle Scholar
- 8.Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, Zhou R, Nesvizhskii A, Chinnaiyan A, Hess JL, Slany RK (2007) A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110(13):4445–4454. https://doi.org/10.1182/blood-2007-05-090514 CrossRefGoogle Scholar
- 9.Martino V, Tonelli R, Montemurro L, Franzoni M, Marino F, Fazzina R, Pession A (2006) Down-regulation of MLL-AF9, MLL and MYC expression is not obligatory for monocyte-macrophage maturation in AML-M5 cell lines carrying t(9;11)(p22;q23). Oncol Rep 15(1):207–211. https://doi.org/10.3892/or.15.1.207 Google Scholar
- 11.Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, Johnstone RW (2016) The CDK9 inhibitor Dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia. Cancer Res 76(5):1158–1169. https://doi.org/10.1158/0008-5472.CAN-15-1070 CrossRefGoogle Scholar
- 13.Johnson AJ, Yeh Y-Y, Smith LL, Wagner AJ, Hessler J, Gupta S, Flynn J, Jones J, Zhang X, Bannerji R, Grever MR, Byrd JC (2012) The novel cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 26(12):2554–2557. https://doi.org/10.1038/leu.2012.144 CrossRefGoogle Scholar
- 14.Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK (2015) Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 125(3):443–448. https://doi.org/10.1182/blood-2014-05-573741 CrossRefGoogle Scholar
- 16.Shao H, Shi S, Huang S, Hole AJ, Abbas AY, Baumli S, Liu X, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C, Wang S (2013) Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. J Med Chem 56:640–659. https://doi.org/10.1021/jm301475f CrossRefGoogle Scholar
- 18.Lam F, Abbas AY, Shao H, Teo T, Adams J, Li P, Bradshaw TD, Fischer PM, Walsby E, Pepper C, Chen Y, Ding J, Wang S (2014) Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget 5(17):7691–7704. https://doi.org/10.18632/oncotarget.2296 CrossRefGoogle Scholar
- 19.Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Kramer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Frohling S (2014) Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 124(1):13–23. https://doi.org/10.1182/blood-2014-02-558114 CrossRefGoogle Scholar
- 20.Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, Basnet SK, Sykes MJ, Albrecht H, Milne R, Wang S (2014) Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation. ChemMedChem 9(5):962–972. https://doi.org/10.1002/cmdc.201300552 CrossRefGoogle Scholar
- 22.Tadesse S, Yu M, Mekonnen LB, Lam F, Islam S, Tomusange K, Rahaman MH, Noll B, Basnet SK, Teo T, Albrecht H, Milne R, Wang S (2017) Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. J Med Chem 60(5):1892–1915. https://doi.org/10.1021/acs.jmedchem.6b01670 CrossRefGoogle Scholar
- 23.Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S (2010) Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood 116(22):4591–4599. https://doi.org/10.1182/blood-2009-10-247239 CrossRefGoogle Scholar
- 24.Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C (2011) Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells. Mol Cancer Ther 10(9):1624–1634. https://doi.org/10.1158/1535-7163.mct-10-1119 CrossRefGoogle Scholar
- 30.Choudhary GS, Al-harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A (2015) MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis 6:e1593. https://doi.org/10.1038/cddis.2014.525 CrossRefGoogle Scholar
- 31.Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP (2015) Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (−)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood 126(3):363–372. https://doi.org/10.1182/blood-2014-10-604975 CrossRefGoogle Scholar
- 33.Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, Alexander WS, Lowe SW, Robb L, Strasser A (2012) Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 26(2):120–125. https://doi.org/10.1101/gad.182980.111 CrossRefGoogle Scholar
- 35.Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Recher C, Wei AH, Guthridge MA (2013) Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood 122(5):738–748. https://doi.org/10.1182/blood-2012-08-447441 CrossRefGoogle Scholar
- 38.Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, Angagaw MH, Wang Y, Long BJ, Lennon XQ, Miselis N, Pucci V, Monahan JW, Lee J, Kondic AG, Im EK, Mauro D, Blanchard R, Gilliland G, Fawell SE, Zawel L, Schuller AG, Strack P (2014) MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. PLoS ONE 9(10):e108371. https://doi.org/10.1371/journal.pone.0108371 CrossRefGoogle Scholar
- 39.De Biasio A, Vrana JA, Zhou P, Qian L, Bieszczad CK, Braley KE, Domina AM, Weintraub SJ, Neveu JM, Lane WS, Craig RW (2007) N-terminal truncation of Antiapoptotic MCL1, but not G2/M-induced phosphorylation, is associated with stabilization and abundant expression in tumor cells. J Biol Chem 282(33):23919–23936. https://doi.org/10.1074/jbc.M700938200 CrossRefGoogle Scholar